| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia N Engl J Med 371 (3), 213-23, 2014 | 1958* | 2014 |
| Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia N Engl J Med 373 (25), 2425-37, 2015 | 1751* | 2015 |
| The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL DC E Matutes, K Owusu-Ankomah, R Morilla, J Garcia Marco, A Houlihan, T H Que leukemia 8 (10), 1640-5, 1994 | 1053 | 1994 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 704 | 2019 |
| Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial JC Byrd, P Hillmen, P Ghia, AP Kater, A Chanan-Khan, RR Furman, ... Journal of clinical oncology 39 (31), 3441-3452, 2021 | 452 | 2021 |
| Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. E Matutes, D Oscier, J Garcia-Marco, J Ellis, A Copplestone, R Gillingham, ... Br J Haematol 92 (2), 382-8, 1996 | 400 | 1996 |
| A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells S Cuní, P Pérez-Aciego, G Pérez-Chacón, JA Vargas, A Sanchez, ... Leukemia 18 (8), 1391-1400, 2004 | 337 | 2004 |
| Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis J Schetelig, A van Biezen, R Brand, D Caballero, R Martino, M Itala, ... Journal of Clinical Oncology 26 (31), 5094-5100, 2008 | 326 | 2008 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 309 | 2020 |
| COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus L Scarfò, T Chatzikonstantinou, GM Rigolin, G Quaresmini, M Motta, ... Leukemia 34 (9), 2354-2363, 2020 | 267 | 2020 |
| PLCG1 mutations in cutaneous T-cell lymphomas JP Vaqué, G Gómez-López, V Monsálvez, I Varela, N Martínez, C Pérez, ... Blood, The Journal of the American Society of Hematology 123 (13), 2034-2043, 2014 | 232 | 2014 |
| Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry S Quijano, A López, J Manuel Sancho, C Panizo, G Debén, C Castilla, ... Journal of Clinical Oncology 27 (9), 1462-1469, 2009 | 229 | 2009 |
| MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by α4β1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in … J Redondo-Munoz, E Escobar-Díaz, R Samaniego, MJ Terol, ... Blood 108 (9), 3143-3151, 2006 | 212 | 2006 |
| Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: Analysis by stage, immunophenotype and morphology TH Que, JA García-Marco, E Matutes, J Ellis, B Brito-Babapulle, S Boyle, ... Blood 82, 571-5, 1993 | 197 | 1993 |
| Unrelated umbilical cord blood transplants in adults: Early recoveryof neutrophils by supportive co-transplantation of a low number of highlypurified peripheral blood CD34+ … MN Fernández, C Regidor, R Cabrera, JA Garcı́a-Marco, R Forés, ... Experimental hematology 31 (6), 535-544, 2003 | 184 | 2003 |
| Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain J Redondo-Muñoz, E Ugarte-Berzal, MJ Terol, PE Van den Steen, ... Cancer cell 17 (2), 160-172, 2010 | 176 | 2010 |
| α4β1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells J Redondo-Munoz, E Ugarte-Berzal, JA García-Marco, MH del Cerro, ... Blood, The Journal of the American Society of Hematology 112 (1), 169-178, 2008 | 168 | 2008 |
| Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia F Bosch, P Abrisqueta, N Villamor, MJ Terol, E González-Barca, C Ferra, ... Journal of clinical oncology 27 (27), 4578-4584, 2009 | 152 | 2009 |
| Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults R Gonzalo-Daganzo, C Regidor, T Martín-Donaire, MA Rico, G Bautista, ... Cytotherapy 11 (3), 278-288, 2009 | 152 | 2009 |
| Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable … D Caballero, JA García-Marco, R Martino, V Mateos, JM Ribera, J Sarrá, ... Clinical cancer research 11 (21), 7757-7763, 2005 | 147 | 2005 |
MARCOS GONZÁLEZ DÍAZServicio de Hematología, Hospital Universitario, Salamanca Spain在 usal.es 的电子邮件经过验证
